KIDNEY TRANSPLANT MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Rising Health Expenditure and Improving Access to Care

Another important driver for the kidney transplant market is the overall increase in health expenditure globally. Rising disposable incomes, growing focus on healthcare as a priority, increasing medical insurance penetration, and better access to healthcare facilities have collectively enabled more patients to afford and qualify for expensive procedures such as kidney transplantation. In developed nations, the overall rise in per capita healthcare spending supports ongoing technological advancements and innovations to improve success rates of organ transplantation. At the same time, developing markets which account for the majority of the disease burden are witnessing increased expenditures on complex transplant surgeries. This is primarily attributed to the extensive primary market research over time by governments and private organizations to elevate standards of medical care and make healthcare affordable for greater population. Consequently, more patients worldwide now have access to various stages of kidney transplantation including pre-transplant evaluation, immunosuppressive therapy post transplantation and long-term medical management- ultimately driving higher demand for related services, devices and drugs.

For instance, on May 25, 2024, AstraZeneca's modeling suggests significant cost savings for health systems in four European countries through early CKD screening and treatment. This could prevent numerous heart attacks, heart failure hospitalizations, and strokes. Studies presented at the ERA Congress support the benefits of targeted screening and guideline-directed treatment, showing potential clinical benefits and cost savings. Real-world evidence from the DISCOVER CKD study reinforces the importance of early treatment, while survey data from the PaCE CKD trial highlights the burden of CKD on patients and caregivers. AstraZeneca is advocating for improved CKD policies globally through initiatives like 'Make the Change for Kidney Health.